Another noncomparative, randomized phase II trial (PICC) evaluated the efficacy of the anti-PD-1 Toripalimab in association or not with Celecoxib (a selective non-steroidal anti-inflammatory drug) for patients affected by locally advanced MMRd/MSI-high CRC. This evidence concerns the gene PDCD1 and colorectal carcinoma.